Retinal Biologics Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4429
Retinal Biologics Market size is projected to experience significant growth from 2019 to 2025.
Retinal biologics are drugs that are derived from living organisms or may contain derivatives from living organisms to treat wide range of retinal disorders. Commonly causing retinal disorders include macular degeneration, diabetic retinopathy, uveitis among several others.
Global Retinal Biologics Market, By Indication
Get more details on this report - Request Free Sample PDF
Growing prevalence of age-related macular degeneration (AMD) will pose to be a major factor highly impacting retinal biologics market growth. As per the American Academy of Ophthalmology estimates, about 15 million North Americans suffer from AMD. The disease may potentially result into central visual acuity loss in one of both eyes in geriatric people. AMD progresses with age, thus increasing the risk of elderly population suffering from the disease. Additionally, rising adoption of smoking and alcohol along with other diseases such as hypertension and hypercholesterolemia will further influence the business growth over the coming years.
Increasing research and development coupled with collaborative strategies among industry players to develop biologics will boost retinal biologics market size in the forthcoming years. In September 2019, Ocugen, Inc., partnered with CanSino Biologics for development of product based on gene therapy for treatment of inherited retinal diseases. CanSino Biologics will provide all chemistry, manufacturing, & controls development and clinical supplies for the development of Ocugen’s first gene therapy. Similarly, IVERIC Bio partnered with Catalent Biologics for manufacturing products for treating orphan inherited retinal disease. Thus, continuous innovations and spending on R&D will offer robust growth potential to retinal biologics business. However, strict regulatory policies coupled with adverse effects of biologics may impede the industry growth over the forecast years.
Tumor necrosis factor (TNF)-a retinal biologics market will witness substantial growth during the forecast years. TNF-a inhibition repairs retinal damage and increases corneal wound healing. These biologics are extensively used in ophthalmology as an alternative to conventional immunosuppressive treatments for non-infectious uveitis. Furthermore, ongoing studies on TNF-a drugs will further augment the segmental growth over the forthcoming period.
Diabetic retinopathy segment will witness rapid growth owing to rising incidence of diabetes mellitus across the globe. It is one of the leading disorders resulting into visual impairment or blindness. The global burden of diabetic retinopathy is high with 93 million people suffering from the disease. Thus, growing consumption of sugar-rich food and sedentary lifestyle will lead to increase in number of diabetic patients, thereby driving the demand for retinal biologics in the future.
Distribution of retinal biologics through specialty clinics will foresee lucrative growth in the upcoming years. Specialty clinics offer high-quality and focused services to the patients. High convenience and accessibility of these clinics further impel the customer preference. Thus, with growing incidence and diagnosis of retinal disorders in specialty clinics, retinal biologics market will witness considerable growth.
U.S. retinal biologics industry is estimated to grow rapidly during the analysis period due to growing prevalence of diabetes and associated diseases resulting into severe retinal disorders. According to the Centers for Disease Control and Prevention, over 100 million adults are living with prediabetes or diabetes in the U.S. Additionally, scientists are investing new ways to treat diabetic macular edema. Thus, growing funding for R&D in the country coupled with risk factors contributing to disease development will influence U.S. retinal biologics market growth over the coming years.
Asia Pacific retinal biologics market will show momentous growth potential during the forecast years. Growing adoption of unhealthy eating and drinking habits in countries including India will impact the demand for retinal biologics. In addition, growing awareness about ophthalmic disorders and treatment alternatives will further drive the market demand.
Novartis AG, OncoGene, Regeneron and Johnson & Johnson (Janssen Pharmaceuticals) are some of the chief market players involved in the global retinal biologics market. These players are undertaking partnerships and product development strategies to expand their business. For instance, in January 2019, Janssen Pharmaceuticals announced about its plan to partner with MeiraGTX Holdings to develop and produce its inherited retinal disease product line, thereby strengthening its ophthalmology business.
Retinal Biologics Market, By Drug Class, 2014-2025 (USD Million)
- TNF-α Inhibitor
- VEGF-A Antagonist
Retinal Biologics Market, By Indication, 2014-2025 (USD Million)
- Macular Degeneration
- Diabetic Retinopathy
Retinal Biologics Market, By Distribution Channel, 2014-2025 (USD Million)
- Specialty clinics
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Amgen, Inc.
- Bausch & Lomb
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Novartis International AG
- Ocular Therapeutix
- Regeneron Pharmaceuticals, Inc.
- Spark Therapeutics
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability